Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Abstract

Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinical trial, Le et al. showed that treatment success is not just limited to colon cancer (see the Perspective by Goswami and Sharma). They found that a wide range of different cancer types with MMR deficiency also responded to PD-1 blockade. The trial included some patients with pancreatic cancer, which is one of the deadliest forms of cancer. The clinical trial is still ongoing, and around 20% of patients have so far achieved a complete response. MMR deficiency appears to be a biomarker for predicting successful treatment outcomes for several solid tumors and indicates a new therapeutic option for patients harboring MMR-deficient cancers. Science , this issue p. 409 ; see also p. 358

Keywords

MeSH Terms

Affiliated Institutions

• Johns Hopkins Medicine US
• Stanford University US
• Providence Health & Services US
• West Virginia University US
• Johns Hopkins Hospital US
• Bloomberg (United States) US
• National Cancer Institute US
• Merck & Co., Inc., Rahway, NJ, USA (United States) US
• The Ohio State University US
• Sidney Kimmel Comprehensive Cancer Center US
• Johns Hopkins University US
• Howard Hughes Medical Institute US
• Swim Across America US
• UPMC Hillman Cancer Center US
• Center for Cancer Research US
• Caris Life Sciences (United States) US

Related Publications